Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.

AIDS (London, England) - 19 Jun 2015

Alessandri-Gradt Elodie, Morgand Marjolaine, Delaugerre Constance, Peytavin Gilles, Sellier Pierre, Simon François, Plantier Jean-Christophe

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active
Share to CD4 Lymphocyte Count
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to Raltegravir Potassium

Share to Viral Load

Source

Identifiers

PMID: 26035328
DOI: 10.1097/QAD.0000000000000703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.PMID 26035328Read ↗

HIV-1 Group O Resistance Against Integrase Inhibitors.Semantic proximity Read ↗

[Mechanisms of HIV drug resistance].Semantic proximity Read ↗

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisSemantic proximity Read ↗

[Resistance development. Are drug resistant HIV-1 minorities relevant for therapeutic success?].Semantic proximity Read ↗

PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".Semantic proximity Read ↗

HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later.Semantic proximity Read ↗

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.Semantic proximity Read ↗

[Is HIV more and more resistant?].Semantic proximity Read ↗

Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)Semantic proximity Read ↗

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Semantic proximity Read ↗

Recent progress in antiretrovirals – lessons from resistanceSemantic proximity Read ↗

Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.